News from aragon pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 04, 2012, 08:00 ET
Aragon Pharmaceuticals is focused on the development of second generation anti-hormonal agents for hormone-driven cancers. The company's portfolio of small molecule therapeutics is based upon pioneering research identifying key molecular events that lead to drug resistance to traditional anti-hormonal therapies. This work has broad implications for the development of breakthrough medicines for prostate cancer and other hormone-dependent cancers. Aragon Pharmaceuticals' most advanced compound, ARN-509, is an androgen receptor antagonist that is currently being evaluated in a Phase 2 trial in patients with castration-resistant prostate cancer. Aragon is a private company founded in 2009.  (PRNewsFoto/Aragon Pharmaceuticals)

Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers

 Aragon Pharmaceuticals Inc. today announced that the company has raised $50 million in a Series D financing to advance the company's pipeline...

Oct 01, 2012, 08:00 ET
Aug 28, 2012, 08:00 ET
Aragon Pharmaceuticals is focused on the development of second generation anti-hormonal agents for hormone-driven cancers. The company's portfolio of small molecule therapeutics is based upon pioneering research identifying key molecular events that lead to drug resistance to traditional anti-hormonal therapies. This work has broad implications for the development of breakthrough medicines for prostate cancer and other hormone-dependent cancers. Aragon Pharmaceuticals' most advanced compound, ARN-509, is an androgen receptor antagonist that is currently being evaluated in a Phase 2 trial in patients with castration-resistant prostate cancer. Aragon is a private company founded in 2009.  (PRNewsFoto/Aragon Pharmaceuticals)

Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director

Aragon Pharmaceuticals today announced the appointment of Faheem Hasnain as an independent director of the Company's board of directors. Mr....

Mar 06, 2012, 07:00 ET

Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers

 Aragon Pharmaceuticals today announced that the company has secured $42 million in an oversubscribed Series C financing to advance Aragon's...

Aug 09, 2010, 08:00 ET

Aragon Pharmaceuticals Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in...

Aug 02, 2010, 08:00 ET

Aragon Pharmaceuticals Appoints Richard A. Heyman CEO

Aragon Pharmaceuticals today announced the appointment of company co-founder Richard A. Heyman, Ph.D., to the role of Chief Executive Officer....

Apr 22, 2010, 08:00 ET

Aragon Pharmaceuticals Secures $22 Million in Series B Financing

Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing. New investor Aisling Capital participated in...

May 20, 2009, 10:30 ET

Aragon Pharmaceuticals Announces $8 Million Series A Financing

Aragon Pharmaceuticals today announced it has raised $8 million in Series A financing led by The Column Group and OrbiMed Advisors. Funds from the...